Format

Send to

Choose Destination
See comment in PubMed Commons below
Endoscopy. 2014 Jun;46(6):465-70. doi: 10.1055/s-0034-1365419. Epub 2014 Apr 25.

Acute renal failure following oral sodium phosphate bowel preparation: a nationwide case-crossover study.

Author information

1
Medical Research Collaborating Center, Seoul National University Hospital/Seoul National University College of Medicine, Seoul, Korea.
2
Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
3
Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.
4
Department of Family Medicine, Health Promotion Center, Seoul National University Bundang Hospital, Bundang, Korea.
5
Department of Family Medicine, Hallym University College of Medicine, Chuncheon, Korea.
6
Korea Institute of Drug Safety and Risk Management, Seoul, Korea.
7
Department of Internal Medicine, Hyewon St. Mary's Hospital, Gumi, Korea.
8
Department of Internal Medicine, Dongguk University College of Medicine, Goyang, Korea.

Abstract

BACKGROUND AND STUDY AIMS:

Oral sodium phosphate (OSP) is a cleansing agent for colonoscopy. Recent reports have cited an increased risk of acute renal failure (ARF) in OSP bowel purgative users, but this risk remains under debate. This study was performed to evaluate the association between OSP and ARF in patients who underwent colonoscopy.

PATIENTS AND METHODS:

A population-based case-crossover study was conducted using the Korean Health Insurance Review and Assessment Service (HIRA) claims data from 1 January 2005 to 31 December 2009. The study population consisted of patients aged ≥ 50 years who underwent colonoscopies after an OSP prescription prior to their first hospitalization for ARF. For each patient, one hazard and four control periods were matched at specified time windows. Conditional logistic regression analysis was used to estimate the odds ratio (OR) and 95 % confidence interval (CI), adjusting for concomitant medications that could induce ARF.

RESULTS:

A total of 1105 patients were included (54 % male). The adjusted ORs for ARF related to the use of OSP when applying the 1-, 2-, 4-, 8-, or 12-week time windows were 3.7 (95 %CI 2.37 - 5.67), 3.5 (95 %CI 2.45 - 4.89), 3.0 (95 %CI 2.30 - 3.95), 2.4 (95 %CI 1.93 - 2.96), and 2.0 (95 %CI 1.69 - 2.46), respectively. When adopting an 8-week time window, the adjusted OR was 2.5 (95 %CI 1.98 - 3.16) for the subgroup without chronic renal failure.

CONCLUSIONS:

The use of OSP was significantly associated with ARF both in patients with and without co-morbidities.

PMID:
24770970
DOI:
10.1055/s-0034-1365419
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Support Center